Abstract: The present invention is related to polymeric materials, in particular thermoplastic or resins, with antifouling, biocidal, antiviral and antimicrobial properties. In particular, the present invention comprises a polymeric material with antimicrobial properties, wherein said antimicrobial property is given by the controlled and maintained in time release of elements or compounds with antimicrobial properties. The present invention also relates to the preparation method and products generated from said polymeric materials with antimicrobial properties.

Abstract: The present invention is related to an additive with biocidal properties based on an active agent with antimicrobial and antifouling properties, wherein the additive corresponds to a supporting material, inert substrate or carrier, which has been modified with antimicrobial agents. The invention further describes the method for modifying the supporting material, inert substrate or carrier, with antimicrobial agents. The resulting additives have a biocidal activity, and can be incorporated in different matrices, such as polymeric resins, either natural or synthetic, thermoplastic or thermostable, organic coatings, ceramics, paintings, varnishes and coatings, granting biocidal activity to those matrices.

Abstract: A pharmaceutical composition is provided having an effective amount of angiotensin-(1-9) and at least one pharmaceutical acceptable carrier, excipient, stabilizer, diluent, and/or adjuvant. Also provided is a method of using the pharmaceutical composition for inhibiting and/or reducing cardiovascular remodeling.

Abstract: The present disclosure describes a study of estrogenic activity present in various plant species, selectively inducing some but not all estrogenic responses in the uterus. Prepubertal female rats were treated sequentially with various extracts or decoctions of different plant species or its vehicle, followed 1 h later by treatment with estradiol-17? (E) or its solvent. Uteri were excised under anesthesia and histologically processed for eosinophil quantification and morphometric evaluation of various uterine responses to estrogen, at 6 or 24 h after hormone or vehicle treatment. Besides extracts or decoctions, pure phytoestrogens were also used. Additionally, human mammary cancer cells MCF-7 or MDAMB-231 were cultured in presence of the extract (or decoction), E, both or solvent and cell proliferation was evaluated.

Abstract: The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogues, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-II converting enzyme (ACE2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide. This vector may be adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene encoding for ACE2.

Abstract: Sustained-release vaginal ring for comprising dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S) or pharmaceutically acceptable thereof as active principle, and optionally a release-modulating agent of the active principle, wherein the amount of active principle is between 1% to 32% by weight, relative to the total weight of the formulation, and the modulator is selected from: polyvinylpyrrolidone K-30, lactose, microcrystalline cellulose and sodium lauryl sulfate. The vaginal ring of the present invention can be used to increase ovarian reserve in women, to be used as drug in assisted reproduction programs, and to relieve symptoms associated with menopause, such as symptoms of vulvar and vaginal atrophy and sexual dysfunction in postmenopausal women.

Abstract: The present invention is directed to an active agent with contraceptive properties which corresponds to a peptide fragment of the Latrodectus mirabilisi's venom. The peptide generally includes the amino acid sequence of SEQ ID NO 2 or sequences that are at least 85% similar, obtained by chemical synthesis or through recombinant DNA technologies. Furthermore, a pharmaceutical contraceptive composition comprising the peptide fragment and one or more pharmaceutically acceptable vehicles is also described. The peptide fragment and pharmaceutical compositions are useful as a contraceptive and spermicide agent.

Abstract: A thin packaging film 1 includes a reference area 2 having a closed contour and which is surrounded over its entire periphery by a tear-off area, an incipient tear 3 being precut in this film so as to intercept this contour while leading into the latter while forming a gripping portion 4 capable of being pulled away from the plane of this thin film, the reference area being designed so as to trap one end of this incipient tear within the contour while the other end propagates by tearing in a spiral from the tear-off area over at least 180° around this reference area when the gripping portion begins to undergo pulling. This closed contour is preferably circular. The closed contour area can in particular be an opening, or a portion of film surrounded by a reinforcement material loop.

Abstract: A method is described for determining eye location on a frontal face digital image in order to validate the frontal face as such and determine points of reference. The method consists of the following steps: obtain a frontal face digital image that is W pixels wide and H pixels high in grayscale, where the top left vertex of the digital image is considered to be the reference source; detect each eye, starting from a search subimage of the frontal face digital image, delivering approximate coordinates if both eyes have been detected, or an arbitrary predetermined value to indicate no eye detection; locate the iris of each eye, if both eyes have been detected, starting from the approximate coordinates, validating the frontal face digital image by delivering eye positions; or, validate the frontal face digital image if one or both eyes have not been detected by submitting a search subimage defined by an area resulting from centering a square of area L in the original image, where L=0.

Abstract: The invention relates to a method for fermenting soy flour in the solid state in order to reduce non-starch polysaccharides and alpha-galactosides, said method comprising the following steps: a) preparation of the fermentation substrate; b) inoculation of the substrate with selected celluloytic bacterial strains; c) incubation; and, optionally, d) drying of the product, which generates a product with: an increase in protein of between 12 and 15% compared to non-fermented soy flour, degradation of the alpha-galactosides of more than 90% compared to non-fermented soy flour, a reduction in non-starch polysaccharides (NSPs) of between 15 and 25%, an amino acid profile similar to that of non-fermented soy flour, and immune-stimulating effects.

Abstract: Fusion protein for immunocastration (Sequences la and Ib) that comprises the primary amino acid sequence of the gonadotrophin-liberating protein fused to a theoretical sequence: Sequence la NH2-QHWSYGLRPGGPPFSGGGGPPFSA-COOH (SEQ ID NO: 1) Sequence Ib NH2-GPPFSGGGGPPFSAQHWSYGLRPG-COOH (SEQ ID NO: 2); DNA sequences coding for said fusion protein; vaccine comprising said fusion protein; use of the fusion protein for mammal immunocastration; process for producing the vaccine; process for preparing the fusion protein that comprises fusing the amino acid sequence of the gonadotrophin-liberating hormone (GnRH-I) to a theoretical glycosilable sequence having immunogenic activity that does not include pathogen or “carrier” protein sequences in its structure.

Abstract: A method of increasing the production of extracellular polymeric substances (EPS) in an Acidithiobacillus ferrooxidans culture is disclosed. The method includes inhibiting an enzyme, such as citrate synthase, aconitase, or isocitrate dehydrogenase, in the tricarboxylic acid (TCA) cycle leading to alpha-ketoglutarate.

Abstract: Sustained-release vaginal ring for comprising dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S) or pharmaceutically acceptable thereof as active principle, and optionally a release-modulating agent of the active principle, wherein the amount of active principle is between 1% to 32% by weight, relative to the total weight of the formulation, and the modulator is selected from: polyvinylpyrrolidone K-30, lactose, microcrystalline cellulose and sodium lauryl sulfate. The vaginal ring of the present invention can be used to increase ovarian reserve in women, to be used as drug in assisted reproduction programs, and to relieve symptoms associated with menopause, such as symptoms of vulvar and vaginal atrophy and sexual dysfunction in postmenopausal women.

Abstract: This invention refers to a pyrometallurgical method for the continuous reduction of oxidized copper through combustion gases in countercurrent to the continuous gravitational flow of liquid copper that disperses through a packed bed reactor with ceramic grains.

Abstract: A biosorbent for removing cationic and/or anionic metals from aqueous solutions, and a process for the production of the biosorbent. The biosorbent includes bacterial aggregates of Bacillus sp. VCHB-10, deposited as NRRL-B-30881, and treated with polyethyleneimine and glutaraldehyde. Among the metals in their cationic form, the following are considered: cations of Ag, Al, Au, Co, Cd, Cu, Cr, Fe, Hg, Mn, Ni, Pb, Pd, Pt, U, Th and Zn. Among the metals in their anionic form, the following are considered: anions of As, Cr and Mo. Removal or recovery of metals from wastewater using the biosorbent is also described.

Abstract: An isolated strain of bacteriophage, specific against bacteria belonging to the Vibrio genre, particularly the anguillarum species, deposited on 3 Oct. 2012 at the Polish Collection of Microorganisms (PCM) of the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences, with access number F/00072, characterized in that said strain is efficient in the prophylaxis, control and/or treatment of the infection caused by Vibrio anguillarum in all types of species of fish, mollusks and crustaceans that are important for aquaculture susceptible to this bacteria, genome size 48.6 Kb, it is not sensitive to chloroform and its storage temperature is ?80° C.

Abstract: The present invention relates to an ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases. At the same time, it is related to a cellular composition that contributes to stimulate the activated antigen-presenting cells to induce a specific immune response against tumors in patients with cancer or other pathologies involving immune responses.

Abstract: The present invention relates to compatibilizers to be used for obtaining materials called polyolefin nanocomposites, microcomposites and polymer blends, and it includes the process for obtaining such compatibilizers. Such compatibilizers are obtained from the monomers of the organic compounds itaconic acid (ITA) or its monooctadecyl itaconate (MODIT) derivative. The compatibilizers are polyolefins grafted with those monomers, which are characterized by having functional groups with a hydrophilic character and a polymer backbone with a hydrophobic character. The compatibilizers of this invention are characterized by having controlled degrees of grafting of these monomers, and they can be used optimally in various applications. It also relates to the process for obtaining such compatibilizers.

Abstract: A thin packaging film 1 includes a reference area 2 having a closed contour and which is surrounded over its entire periphery by a tear-off area, an incipient tear 3 being precut in this film so as to intercept this contour while leading into the latter while forming a gripping portion 4 capable of being pulled away from the plane of this thin film, the reference area being designed so as to trap one end of this incipient tear within the contour while the other end propagates by tearing in a spiral from the tear-off area over at least 180° around this reference area when the gripping portion begins to undergo pulling. This closed contour is preferably circular. The closed contour area can in particular be an opening, or a portion of film surrounded by a reinforcement material loop.

Abstract: Method for the prevention of the tau protein aggregation and treating Alzheimer's disease by administering a quinoline derivative compound of formula wherein R2 is 2-(4-aminophenyl) or 2-(4-methylphenyl) and R6 is methyl as an inhibitor of the tau protein aggregation.